VENTYX BIOSCIENCES, INC. VTYX 深 滬
等待開盤 09-10 09:30:00 美东时间
2.38
0.000
0.00%
華盛通- 最 高2.54
- 今 開2.34
- 成交量 71.57万股
- 最 低 2.3064
- 昨 收 2.38
- 總市值 1.70亿
- 52周最高 3.39
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.783
- 委 比 1.79%
- 總股本 7130.85万
- 歷史最高 47.2508
- 量 比 1.78
- 振 幅 9.82%
- 歷史最低 0.783
- 每 手 1
- 風險率 3.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences executives will participate in three upcoming investor conferences: the 2025 Wells Fargo Healthcare Conference in Boston on September 5, and both the Morgan Stanley 23rd Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8. A webcast of the Wells Fargo presentation will be available on the company's website, www.ventyxbio.com, with a replay accessible fo...
08-27 11:02
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
Ventyx Biosciences Q2 EPS $(0.38) Beats $(0.45) Estimate
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.45) by 16.11 percent. This is a 15.56 percent increase over losses of $(0.45) per share
08-08 04:50
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences reported positive Phase 2a data for VTX3232 in early-stage Parkinson’s disease, demonstrating safety, high CSF drug exposure, and biomarker suppression. VTX2735 Phase 2 data in recurrent pericarditis are expected in Q4 2025. VTX3232’s Phase 2 study in obesity and cardiometabolic risk is fully enrolled, with Q4 2025 results anticipated. The company has $209 million in cash, supporting operations into H2 2026.
08-07 20:05
Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial
Ventyx Biosciences (NASDAQ:VTYX) announced Tuesday that a small mid-stage trial for VTX3232, its experimental therapy for Parkinson’s disease, reached the primary endpoint related to safety and tolera...
06-17 19:48
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232 in early-stage Parkinson's disease. The study achieved its primary goal of demonstrating safety and tolerability, with no drug-related adverse events. VTX3232 showed high drug exposures in both plasma and CSF, along with significant reductions in NLRP3-related biomarkers, indicating sustained target engagement. Patients also experienced improvements in motor and non-...
06-17 11:00
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, announced that its executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, in New York. The event will be webcast and available for replay on the company's website. Ventyx specializes in NLRP3 inhibitors and inflammatory bowel disease therapies,...
05-28 12:00
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Vigil Neuroscience (NASDAQ:VIGL) stock increased by 243.7% to $7.94 du...
05-22 20:10
Ventyx Biosciences Q1 EPS $(0.39) Beats $(0.49) Estimate
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.49) by 20.41 percent. This is a 37.1 percent increase over losses of $(0.62) per share from
05-09 04:27
Viking among notable gainers as Pfizer raises deal prospects
Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after Pfizer (NYSE:PFE) CEO Albert Bourla indicated plans to seek deals to add cardiom...
04-30 03:26
